Company

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

SEP 4, 2026 · PHASE 3 TRIAL

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

ClinicalTrials.gov

This is a registry record for a Phase 3 trial currently recruiting; no results are posted, so evidence strength cannot be assessed.

PreliminaryKaruna Therapeutics, Inc., a Bristol Myers Squibb company KarXT Psychosis Associated With Alzheimer's Disease

Reported

Planned enrollment500

PhasePhase 3

Primary outcome measureChange from Baseline to End of Treatment in…

AUG 17, 2026 · PHASE 3 TRIAL

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

ClinicalTrials.gov

This is a clinical trial registry record describing a planned Phase 3 study with no results yet reported; the protocol and design are established but outcome data are absent.

PreliminaryNCT05511363 Karuna Therapeutics, Inc., a Bristol Myers Squibb company KarXT

Reported

Planned enrollment410

Study duration38 weeks

Primary outcome measureTime from randomization to relapse at Week…